| A phase 3 trial of bevacizumab in ovarian cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2687 | 2011 |
| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2644 | 2016 |
| ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ... International Journal of Gynecologic Cancer 26 (1), 2016 | 2044 | 2016 |
| Niraparib in patients with newly diagnosed advanced ovarian cancer A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ... New England Journal of Medicine 381 (25), 2391-2402, 2019 | 2027 | 2019 |
| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ... Journal of clinical oncology 32 (13), 1302-1308, 2014 | 1793 | 2014 |
| ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma N Concin, X Matias-Guiu, I Vergote, D Cibula, MR Mirza, S Marnitz, ... International Journal of Gynecologic Cancer 31 (1), 2021 | 1783 | 2021 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ... Annals of oncology 30 (5), 672-705, 2019 | 1263 | 2019 |
| Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ... The Lancet Oncology 16 (8), 928-936, 2015 | 984 | 2015 |
| Dostarlimab for primary advanced or recurrent endometrial cancer MR Mirza, DM Chase, BM Slomovitz, R dePont Christensen, Z Novák, ... New England Journal of Medicine 388 (23), 2145-2158, 2023 | 462 | 2023 |
| Cancer of the corpus uteri F Amant, MR Mirza, M Koskas, CL Creutzberg International Journal of Gynecology & Obstetrics 143, 37-50, 2018 | 442 | 2018 |
| Incorporation of pazopanib in maintenance therapy of ovarian cancer A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ... Journal of clinical oncology 32 (30), 3374-3382, 2014 | 393 | 2014 |
| Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up A Oaknin, TJ Bosse, CL Creutzberg, G Giornelli, P Harter, F Joly, ... Annals of oncology 33 (9), 860-877, 2022 | 391 | 2022 |
| Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm … RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ... The Lancet Oncology 22 (5), 609-619, 2021 | 324 | 2021 |
| ESMO-ESGO-ESTRO endometrial consensus conference working group N Colombo, C Creutzberg, F Amant, T Bosse, A Gonzalez-Martin, ... ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis …, 2016 | 324 | 2016 |
| The forefront of ovarian cancer therapy: update on PARP inhibitors MR Mirza, RL Coleman, A González-Martín, KN Moore, N Colombo, ... Annals of Oncology 31 (9), 1148-1159, 2020 | 303 | 2020 |
| Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: recurrent disease MK Wilson, E Pujade-Lauraine, D Aoki, MR Mirza, D Lorusso, AM Oza, ... Annals of Oncology 28 (4), 727-732, 2017 | 267 | 2017 |
| Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the … J Pfisterer, B Weber, A Reuss, R Kimmig, A Du Bois, U Wagner, ... Journal of the National Cancer Institute 98 (15), 1036-1045, 2006 | 264 | 2006 |
| Cancer of the corpus uteri: 2021 update M Koskas, F Amant, MR Mirza, CL Creutzberg International Journal of Gynecology & Obstetrics 155, 45-60, 2021 | 257 | 2021 |
| Randomized trial of cytoreductive surgery for relapsed ovarian cancer P Harter, J Sehouli, I Vergote, G Ferron, A Reuss, W Meier, S Greggi, ... New England Journal of Medicine 385 (23), 2123-2131, 2021 | 255 | 2021 |
| Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial MR Mirza, EÅ Lundqvist, MJ Birrer, RP Christensen, GB Nyvang, ... The Lancet Oncology 20 (10), 1409-1419, 2019 | 245 | 2019 |
Ignace VergoteProfessor of Gynecologic Oncology, University of LeuvenVerified email at uzleuven.be